New York, NYNCT04987775Now EnrollingIRB Ready

Gulf War Syndrome Clinical Trial in New York, NY

Access cutting-edge gulf war syndrome treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Nova Southeastern University

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access gulf war syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gulf war syndrome treatment provided free

Apply for This New York Location

Check if you qualify for this gulf war syndrome clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Gulf War Syndrome Study in New York

This mechanistic study will test if NAC affects chronic oxidative stress and depletion of antioxidants in GWI participants. Blood specimen collection and neuroimaging will be used to determine whether NAC affects serum glutathione (GSH) concentration and oxidative stress in the CNS when compared to placebo.

Sponsor: Nova Southeastern University

Who Can Participate

Inclusion Criteria

47 to 70 years
Served in the Gulf War Theater for any period between August 1990 and July 1991.
Meets modified Kansas case definition criteria for Gulf War Illness. The modified Kansas definition includes the following:
Allowance of normal illness of aging, such as hypertension and diabetes, if the conditions are treated and are in demonstrable stable and normal ranges at the time of screening and assessment.
Allowance of stable comorbid conditions such as Post Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and mild Traumatic Brain Injury (mTBI) that have not required hospitalization in the 2 years prior to recruitment. Severe TBI is excluded.
Able to provide written consent to the study
Agrees to participate in follow-up visits.

Exclusion Criteria

Self-report of current treated or untreated major depression with psychotic or melancholic features (as determined by self-report and Hamilton Depression Inventory (Ham-D)), schizophrenia, bipolar disorder, delusional disorders, dementias of any type, or a history of central nervous system (CNS) disorders that may affect cognitive function (e.g., epilepsy, stroke, brain tumor, multiple sclerosis, Parkinson's Disease, Alzheimer's disease), or alcoholism or drug abuse
Severe claustrophobia or serious difficulty being in an MRI scanner or other enclosed space (MRS substudy only)
Presence of ferrous implanted medical devices or metal fragments or objects that are embedded under the skin (MRS substudy only)
Current heavy alcohol or tobacco use (self-report). Alcohol consumption not to exceed approximately 15 drinks per week (with a drink defined as 12 oz beer, 5 oz wine, or 1.5 oz distilled spirits) and tobacco use not to exceed 20 cigarettes (or equivalent) per day.
Chronic active infections such as HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) (self-report or antibody titer)
Renal disease (self-report or laboratory results: renal insufficiency with serum creatinine \> 2.0 mg/dL)
Liver disease (self-report or laboratory results: hepatic insufficiency (bilirubin \>2.5mg/dL or transaminases \> 3 times the upper limits of normal)
Uncontrolled diabetes (HgbA1c \> 7.5) without adequate medical care. Individuals with HgbA1c \> 7.5 will be reviewed and judged by the PI or delegate; if potential participant has adequate medical care to manage diabetes, enrollment is allowed; otherwise HgbA1c \> 7.5 is exclusionary
Diagnosed vascular disease (including congestive heart failure)
Diagnosed bleeding disorders or use of blood-thinning medications
Receipt of stavudine or didanosine for more than 7 days within 30 days prior to screening
Currently have exclusionary diagnoses that could reasonably explain the symptoms of their fatiguing illness and their severity
Are scheduled for a surgery during the period of study participation or had surgery within 6 weeks prior to screening
Pregnant (women only) Prohibited Concomitant or Prior Therapies
Currently on dialysis
Previous or current receipt of any antiviral medication, such as pegylated interferon, ribavirin, entecavir, tenofovir, or didanosine for more than 7 days within 30 days prior to screening
Participating in another interventional (including social-behavioral therapy) clinical trial of an investigational therapy within 6 weeks prior to consent, or planning to participate in another interventional clinical trial of an investigational therapy during the course of this study
Any herbal medicine within 30 days prior to consent and screening blood draw

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT04987775) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gulf War Syndrome Treatment Options in New York, NY

If you're searching for gulf war syndrome treatment options in New York, NY, this clinical trial (NCT04987775) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gulf war syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gulf war syndrome clinical trials near you to find additional studies recruiting in your area.

More Myalgic Encephalomyelitis Trials in New York, NY

See all myalgic encephalomyelitis clinical trials recruiting in New York — not just this study.

Browse Myalgic Encephalomyelitis Trials in New York →

Browse More Trials by Condition

Myalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY